jag009
★★★

NJ,
2012-03-15 20:05
(4422 d 06:21 ago)

Posting: # 8280
Views: 6,481
 

 Determining Elimination Constant (Kel) [NCA / SHAM]

Hi,

Would someone give me some idea on the following case?

It sounds a bit simple but what is the proper way to determine Kel from the elimination phase, based on noncompartmental analysis, if the last measurable timepoint has a higher concentration than the adjacent timepoint? Should Kel be labelled as "Undefined"? Some CROs would say "Undefined" but there are others who would determine Kel as long as the linear regression result based on the timepoints involved (at least 3) is acceptable.

Thanks

Edit: Category changed. [Helmut]
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2012-03-16 02:46
(4421 d 23:40 ago)

@ jag009
Posting: # 8281
Views: 5,754
 

 Ci > Ci-1 (excluding data points)

Dear Jag!

❝ […] what is the proper way to determine Kel from the elimination phase, based on noncompartmental analysis, if the last measurable timepoint has a higher concentration than the adjacent timepoint?


Proper? Two pharmacokineticists = ≥3 methods. ;-)

❝ Should Kel be labelled as "Undefined"? Some CROs would say "Undefined" …


That would mean excluding the subject’s AUCs (AUCt unreliable, AUC undefined). At least you could keep the subject’s Cmax in the data set (which is more variable).

❝ … but there are others who would determine Kel as long as the linear regression result based on the timepoints involved (at least 3) is acceptable.


Others = most, IMHO. As long as you are consistent, perform the estimation of λz blinded for treatment, and have an SOP in place it shouldn’t be problematic.* PK software by default mark excluded datapoints both in the plots and tabulated output. A moderately higher last value is not that uncommon, especially if the last sampling interval is relatively short compared to the half-life. Just think about acceptable analytical (in)accuracy and (im)precision: 15% within the calibration range and 20% at the LLOQ.

Example: t½ 8 h, last two sampling points (interval = t½)
    theoret.  ±inacc/±imprec.  obs.
16    25         -2× 15%       17.5
24    12.5       +2× 20%       17.5

Even if the method is performing within specs, two values with deviations of opposite direction already lead to equal concentrations. A little bit more random noise and voilà!


  • A friend told me that he once saw an SOP essentially stating: “Select datapoints in such a way that the residual AUC is <20% of AUC.” Of course that’s not an outstanding clever idea.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
jag009
★★★

NJ,
2012-03-26 17:24
(4411 d 10:02 ago)

@ Helmut
Posting: # 8335
Views: 5,305
 

 Ci > Ci-1 (excluding data points)

Hi Helmut,

❝ ❝ Should Kel be labelled as "Undefined"? Some CROs would say "Undefined" …


❝ That would mean excluding the subject’s AUCs (AUCt unreliable, AUC undefined). At least you could keep the subject’s Cmax in the data set (which is more variable).


Actually that particular CRO (maybe there are others) kept the subject's Cmax, Tmax and AUCt but assigned AUCinf, kel and t1/2 as undefined or "N.C."

One more question, what if the last two points of the elimination phase is going in the positive direction and the points before them (lets say 3 points, yes after Cmax) are declining?
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2012-03-28 16:30
(4409 d 10:56 ago)

@ jag009
Posting: # 8338
Views: 5,365
 

 Unreliable AUCt

Dear John!

❝ ❝ That would mean excluding the subject’s AUCs (AUCt unreliable, AUC undefined). At least you could keep the subject’s Cmax in the data set (which is more variable).


❝ Actually that particular CRO (maybe there are others) kept the subject's Cmax, Tmax and AUCt but assigned AUCinf, kel and t1/2 as undefined or "N.C."


That doesn’t make sense from a (European) regulatory perspective, IMHO. For EMA the primary metric for extent of absorption is AUCt, but you have to demonstrate that it’s a reliable estimate: AUCt/AUC ≥0.8. For IR products this does not make sense, since absorption is expected to be already complete after 2–4×tmax. After this cut-off point estimates are stable, only variability increases (see papers by Endrényi, Midha, Tóthfalusi).
Interesting enough FDA (where both AUCt and AUC are primary metrics) no clear statement is made about AUCt. We find only:

[…] we recommend that 12 to 18 samples, including a predose sample, be collected per subject per dose. This sampling can continue for at least three or more terminal half lives of the drug. […] The sample collection can be spaced in such a way that the […] terminal elimination rate constant (λz) can be estimated accurately. At least three to four samples can be obtained during the terminal log-linear phase to obtain an accurate estimate of λz from linear regression.

It seems that AUCt can be kept in the analysis.

❝ One more question, what if the last two points of the elimination phase is going in the positive direction and the points before them (lets say 3 points, yes after Cmax) are declining?


Good question, next question. ;-) For the FDA I would trigger reanalysis (pharmacokinetic repeat) – SOP in place, no cherry-picking (blinded for treatment), justification in the report which value was used in the final analysis.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
ElMaestro
★★★

Denmark,
2012-03-29 20:57
(4408 d 06:29 ago)

@ jag009
Posting: # 8348
Views: 5,344
 

 Ci > Ci-1 (excluding data points)

Hello Jag,

❝ One more question, what if the last two points of the elimination phase is going in the positive direction and the points before them (lets say 3 points, yes after Cmax) are declining?


This happens actually quite frequently in inhalation and nasal BE studies.
It really, really stinks and is PP implausible when the last value is 3x the previous one and the preceding 6 values have been dropping nicely etc. Plausibility (or foul smell for that matter) is, however, not always a good reason to ignore anything. Therefore more meat to the bone is necessary.

When I see it I usually tell my clients to have a look at the bioanalytical validation and possibly consider an audit. Silly clients will flat out refuse auditing* while wiser clients will do it. Once the dust settles things sometimes make more sense.

Best regards,
EM.

* typical excuses:
  1. "We have contracted with this lab previously and we have no reason to suspect any deviations." (But if you further ask if they have audited the supplier the answer is often no. Absence of evidence vs evidence of absence....).
  2. "The Virgin Island's Drug Agency (or whatever) inspected the bioanalytical lab in 1957 so we don't need to audit".
  3. "Their QC-head's son was on the same soccer team as my son in pre-school. You should've seen them when they hammered Snottsville 3-0 back in 1982. Definitely no worry here."
UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,655 registered users;
56 visitors (0 registered, 56 guests [including 7 identified bots]).
Forum time: 03:27 CEST (Europe/Vienna)

So far as I can remember,
there is not one word in the Gospels
in praise of intelligence.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5